Accession Number: | 0001209191-20-013020 |
Date: | 2020-02-24 |
Issuer: | VERTEX PHARMACEUTICALS INC / MA (VRTX) |
Original Submission Date: |
ARBUCKLE STUART A
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON, MA 02210
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2020-02-24 | F | 2,898 | d | $239.23 | 38,813 | direct | ||
COMMON STOCK | 2020-02-25 | S | 810 | d | $229.78 | 38,003 | direct | ||
COMMON STOCK | 2020-02-25 | S | 432 | d | $230.85 | 37,571 | direct | ||
COMMON STOCK | 2020-02-25 | S | 360 | d | $232.35 | 37,211 | direct | ||
COMMON STOCK | 2020-02-25 | S | 420 | d | $234.08 | 36,791 | direct | ||
COMMON STOCK | 2020-02-25 | S | 540 | d | $235.14 | 36,251 | direct | ||
COMMON STOCK | 2020-02-25 | S | 420 | d | $236.36 | 35,831 | direct | ||
COMMON STOCK | 2020-02-25 | S | 20 | d | $236.88 | 35,811 | direct | ||
COMMON STOCK | 2020-02-25 | S | 632 | d | $238.33 | 35,179 | direct | ||
COMMON STOCK | 2020-02-24 | 0 | $0.00 | 140 | indirect |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|
ID | footnote |
---|---|
f1 | transaction made pursuant to mr. arbuckle's company approved trading plan under rule 10b5-1. |
f2 | open market sales reported on this line occurred at a weighted average price of $229.78 (range $229.21 to $230.14). |
f3 | mr. arbuckle undertakes to provide (upon request by the sec staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
f4 | open market sales reported on this line occurred at a weighted average price of $230.85 (range $230.51 to $231.30). |
f5 | open market sales reported on this line occurred at a weighted average price of $232.35 (range $232.03 to $232.72). |
f6 | open market sales reported on this line occurred at a weighted average price of $234.08 (range $233.57 to $234.44). |
f7 | open market sales reported on this line occurred at a weighted average price of $235.14 (range $234.61 to $235.56). |
f8 | open market sales reported on this line occurred at a weighted average price of $236.36 (range $235.69 to $236.65). |
f9 | open market sales reported on this line occurred at a weighted average price of $238.33 (range $237.98 to $238.54). |